Pareto has downgraded its recommendation for hygiene and health company Essity to hold from buy, and lowered its target price to 270 kronor from 295 following last week's fourth-quarter report.

The analysis firm notes that the company's relative valuation compared to the broader market remains strong and that margins were solid in the report. However, they see a lack of catalysts for the stock due to limited short-term growth prospects.

"Although the results were somewhat better than expected, this was mainly due to the mix, while underlying growth remains weak. We have slightly reduced our forecasts due to weaker growth prospects," the report states.